Denmark, which recently discontinued use of the AstraZeneca PLC COVID-19 vaccine over rare blood-clotting issues, said Monday it has also decided it will not use the vaccine developed by Johnson & Johnson, also due to worries about blood clots,AFP reported. Danish health officials said the favorable epidemiological situation in the country meant it can rely completely on the two vaccines developed by Pfizer Inc. and German partner BioNTech SE and by Moderna Inc. , which use the same mRNA technology and have not been associated with the same blood-clotting issue. The European Medicines Agency and the World Health Organization have both recommended the J&J vaccine on the basis that the benefits outweigh the risks. The health authority noted Denmark’s epidemic was currently “under control,” and that “the vaccination rollout is progressing satisfactorily with other available vaccines.” J&J shares were up 1.3% Monday and have gained about 5% in the year to date, while the S&P 500 has gained about 12%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
